Bionime Corp (4737) - Total Assets
Based on the latest financial reports, Bionime Corp (4737) holds total assets worth NT$5.65 Billion TWD (≈ $178.16 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Bionime Corp - Total Assets Trend (2009–2025)
This chart illustrates how Bionime Corp's total assets have evolved over time, based on quarterly financial data. Also see 4737 company net worth for the company's overall valuation and market capitalisation.
Bionime Corp - Asset Composition Analysis
Current Asset Composition (December 2025)
Bionime Corp's total assets of NT$5.65 Billion consist of 27.4% current assets and 72.6% non-current assets. Review debt load of Bionime Corp to assess the company's total debt and financial obligations.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 7.4% |
| Accounts Receivable | NT$540.54 Million | 9.5% |
| Inventory | NT$456.41 Million | 8.0% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$919.39 Million | 16.1% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2009–2025)
This chart illustrates how Bionime Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Bionime Corp (4737) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bionime Corp's current assets represent 27.4% of total assets in 2025, a decrease from 80.9% in 2009.
- Cash Position: Cash and equivalents constituted 7.4% of total assets in 2025, down from 39.0% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 16.0% of total assets, an increase from 0.0% in 2009.
- Asset Diversification: The largest asset category is intangible assets at 16.1% of total assets.
Bionime Corp Competitors by Total Assets
Key competitors of Bionime Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Gan & Lee Pharmaceuticals Co Ltd
SHG:603087
|
China | CN¥12.68 Billion |
|
Andon Health Co Ltd
SHE:002432
|
China | CN¥29.91 Billion |
|
Shenyang Xingqi Pharmaceutical Co Ltd
SHE:300573
|
China | CN¥2.42 Billion |
|
Pegavision
TW:6491
|
Taiwan | NT$16.17 Billion |
|
Nanosonics Ltd
AU:NAN
|
Australia | AU$279.25 Million |
|
Visco Vision Inc.
TW:6782
|
Taiwan | NT$5.82 Billion |
|
QITIAN Technology Group Co Ltd
SHE:300061
|
China | CN¥1.17 Billion |
|
Embecta Corp
NASDAQ:EMBC
|
USA | $1.27 Billion |
Bionime Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.85 | 0.84 | 1.12 |
| Quick Ratio | 0.57 | 0.53 | 0.67 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$-266.38 Million | NT$-325.53 Million | NT$148.02 Million |
Bionime Corp - Advanced Valuation Insights
This section examines the relationship between Bionime Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.98 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | -1.3% |
| Total Assets | NT$5.70 Billion |
| Market Capitalization | $137.57 Million USD |
Valuation Analysis
Below Book Valuation: The market values Bionime Corp's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Bionime Corp's assets decreased by 1.3% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Bionime Corp (2009–2025)
The table below shows the annual total assets of Bionime Corp from 2009 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | NT$5.70 Billion ≈ $179.72 Million |
-1.33% |
| 2024-12-31 | NT$5.78 Billion ≈ $182.14 Million |
+9.07% |
| 2023-12-31 | NT$5.30 Billion ≈ $167.00 Million |
+6.37% |
| 2022-12-31 | NT$4.98 Billion ≈ $156.99 Million |
+9.18% |
| 2021-12-31 | NT$4.56 Billion ≈ $143.79 Million |
+1.76% |
| 2020-12-31 | NT$4.49 Billion ≈ $141.30 Million |
+1.83% |
| 2019-12-31 | NT$4.40 Billion ≈ $138.76 Million |
-4.03% |
| 2018-12-31 | NT$4.59 Billion ≈ $144.59 Million |
+4.90% |
| 2017-12-31 | NT$4.37 Billion ≈ $137.83 Million |
-5.85% |
| 2016-12-31 | NT$4.65 Billion ≈ $146.39 Million |
+1.74% |
| 2015-12-31 | NT$4.57 Billion ≈ $143.89 Million |
-2.14% |
| 2014-12-31 | NT$4.67 Billion ≈ $147.04 Million |
+3.16% |
| 2013-12-31 | NT$4.52 Billion ≈ $142.54 Million |
+24.56% |
| 2012-12-31 | NT$3.63 Billion ≈ $114.43 Million |
+27.40% |
| 2011-12-31 | NT$2.85 Billion ≈ $89.82 Million |
+121.51% |
| 2010-12-31 | NT$1.29 Billion ≈ $40.55 Million |
+44.28% |
| 2009-12-31 | NT$892.09 Million ≈ $28.11 Million |
-- |
About Bionime Corp
Bionime Corporation designs, manufactures, and sells medical instruments in China, Switzerland, the United States, Belarus, Algeria, the United Arab Emirates, Egypt, and internationally. The company manufactures and sells blood glucose meters and test strips to medical equipment companies, pharmacies, and hospitals, as well as offering blood glucose monitoring devices and systems under the RIGHTE… Read more